By Gilang Cahya 
Johns Hopkins Medicine scientists have made a significant breakthrough in understanding the gastrointestinal distress associated with COVID-19, identifying key molecular mechanisms behind the diarrhea experienced by many infected individuals. Utilizing human stem cells engineered to form "mini-intestines" in a laboratory setting, researchers have elucidated how the SARS-CoV-2 virus disrupts normal intestinal function, offering potential avenues for therapeutic intervention. These findings, detailed in the July 30th issue of Cellular and Molecular Gastroenterology and Hepatology, shed light on a common yet often perplexing symptom of the virus.
The Pervasive Impact of COVID-19 on the Gut
The COVID-19 pandemic, which began with the initial outbreak in late 2019, has been characterized by a wide array of symptoms, ranging from the well-known respiratory issues like fever, cough, and shortness of breath, to a significant gastrointestinal impact. While the respiratory manifestations have garnered the most attention, up to half of individuals infected with SARS-CoV-2 have reported experiencing diarrhea. This symptom, while not typically life-threatening in the same vein as diseases like cholera, can serve as an indicator of disease severity and, importantly, a predictor of long COVID.
Long COVID, a condition affecting an estimated 30% of those who contract the virus, is marked by a persistent and often debilitating array of symptoms that can linger for months or even years. These can include chronic pain, cognitive impairment often referred to as "brain fog," persistent shortness of breath, chest pain, and profound fatigue. The presence of gastrointestinal symptoms, such as diarrhea, has increasingly been recognized as a potential harbinger of these prolonged health challenges.
Dr. Mark Donowitz, Emeritus Professor of Medicine and Physiology at the Johns Hopkins University School of Medicine, emphasized the clinical significance of COVID-19-related diarrhea. "While COVID-19 diarrhea is not life-threatening like cholera, it can often predict a severe case and also who gets the long COVID syndrome," he stated, underscoring the need for a deeper understanding of its underlying causes.
Unraveling the Viral Intrusion: ACE2 and TMPRSS2 in the Intestine
Previous research had established that the SARS-CoV-2 virus gains entry into human cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. This enzyme is not confined to the respiratory system but is also present in significant quantities within the intestinal lining. Another crucial enzyme, TMPRSS2, which facilitates the virus’s entry into cells by priming the spike protein, is also found in the gut. However, the precise molecular pathways through which the virus triggers diarrhea remained largely unknown until this recent study.
The Johns Hopkins research team leveraged a sophisticated in vitro model of human intestinal tissue known as enteroids. These three-dimensional structures are derived from human stem cells and are cultivated to mimic the complex cellular architecture and function of the normal human intestine. By stimulating these stem cells, researchers can generate enteroids that consist of a single layer of intestinal cells, oriented in the same functional direction as their in vivo counterparts. This "mini-intestine-in-a-dish" model provides a unique and powerful platform for studying viral interactions with intestinal cells without the complexities of a whole organism.
Experimental Findings: Disruption of Cellular Transport and Inflammation
The researchers exposed these enteroids to live SARS-CoV-2 virus. The subsequent analysis revealed significant alterations in the protein expression and overall function of the intestinal cells. This direct observation provided concrete evidence of the virus’s impact on the gut at a molecular level.
In typical diarrheal conditions, whether caused by bacterial infections, other viruses, or adverse reactions to medications, the underlying mechanism often involves disruptions in transport proteins. These proteins are responsible for moving essential molecules, such as sodium and chloride, across the cell membranes that line the intestine. Such disruptions typically lead to a reduction in sodium and chloride absorption from the gut lumen into the bloodstream, coupled with an increase in chloride secretion into the lumen, resulting in watery stools.
The Johns Hopkins study found that COVID-19 diarrhea exhibits both of these characteristics, a common feature across various diarrheal diseases. However, a key distinction emerged: while many diarrheal diseases involve the activation of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in chloride secretion, the researchers identified that in COVID-19 diarrhea, a different class of proteins, specifically calcium-activated chloride channels (CaCCs), were primarily responsible for this enhanced chloride secretion. This finding is significant as it points to a distinct molecular pathway affected by SARS-CoV-2 compared to other common causes of diarrhea.
A Dual Threat: Direct Viral Effects and Inflammatory Response
Furthermore, the study uncovered an unusual aspect of COVID-19-induced diarrhea: a combination of direct viral effects on transport proteins and an accompanying inflammatory response. This dual mechanism is less commonly observed in other diarrheal diseases, which are often characterized by either direct cellular damage or a purely inflammatory process.
The researchers hypothesize that the inflammation triggered by SARS-CoV-2 in the gut may mirror the inflammatory processes observed in the lungs and other organs affected by the virus. This suggests that strategies aimed at modulating the inflammatory response could be a promising therapeutic approach for managing COVID-19-related diarrhea. The implication is that therapies targeting the inflammatory cascade, similar to those being explored for respiratory complications, might also offer relief for gastrointestinal symptoms.
Implications for Long COVID and Future Research
The study’s findings hold significant implications for understanding and potentially treating long COVID. Dr. Donowitz highlighted the ongoing mystery surrounding the precise mechanisms of long COVID, acknowledging that the virus can persist in the intestine for extended periods. "The next big question is to determine what exactly allows the virus to live in the intestine and what allows the virus to live over a long period of time," he remarked.
The identification of specific molecular pathways involved in viral entry and the subsequent disruption of intestinal function provides a crucial foundation for further research into viral persistence. Understanding how SARS-CoV-2 establishes and maintains itself within the intestinal environment is critical for developing strategies to clear the virus and alleviate long-term symptoms. This could involve targeting specific viral proteins, cellular receptors, or inflammatory pathways that facilitate viral survival.
Broader Impact and Potential Therapeutic Strategies
The research offers a tangible basis for developing targeted therapies for COVID-19-related diarrhea. By pinpointing the role of calcium-activated chloride channels, drug developers could potentially design inhibitors or modulators of these channels to restore normal intestinal function. Similarly, by understanding the inflammatory component, new anti-inflammatory agents could be explored specifically for their efficacy in the gut.
The study’s reliance on the enteroid model underscores the growing importance of organoid technology in biomedical research. These "organoids-on-a-chip" and similar advanced in vitro models are proving invaluable for dissecting complex biological processes and testing potential drug candidates in a more physiologically relevant context than traditional cell cultures. The success of this research in enteroids suggests that this model system will continue to play a pivotal role in unraveling the complexities of infectious diseases and their impact on various organ systems.
A Collaborative Endeavor
This significant research was made possible through a collaborative effort and was supported in part by funding from the Johns Hopkins University School of Medicine Dean Durso Award and the National Institutes of Health, specifically the National Institute of Diabetes and Digestive and Kidney Diseases (grants R01 DK26523, R01 DK116352; and P30DK089502).
The study’s authors represent a multidisciplinary team from Johns Hopkins Medicine, the Johns Hopkins Bloomberg School of Public Health, and the University of New Mexico Health Sciences Center and Center for Global Health. This broad collaboration highlights the complex and multifaceted nature of tackling global health challenges like the COVID-19 pandemic. The diverse expertise brought to bear on this problem, from molecular biology and gastroenterology to public health and virology, has been instrumental in achieving these groundbreaking insights. The research team included Chung-Ming Tse, Rafiq Sarker, Ruxian Lin, Tyrus Vong, G. McNamara, Varsha Singh, Chenxu Guo, Shang Jui Tsai, Andrew Karaba, Andrea Cox, Steven Gould, Olga Kovbasnjuk, and Nicholas C. Zachos from Johns Hopkins Medicine; Jaiprasath Sachithanandhan and Andy Pekosz from the Johns Hopkins Bloomberg School of Public Health; Karol Dokladny, Manmeet Rawat, Julie In, Alison Kell, and Steven Bradfute from the University of New Mexico Health Sciences Center; and Ivy Horwitz and Chun Yan Ye from the University of New Mexico Center for Global Health.
Looking Ahead: A Path Towards Relief and Recovery
The identification of specific molecular mechanisms for COVID-19-related diarrhea marks a critical step forward in understanding the full spectrum of this disease. By dissecting how SARS-CoV-2 disrupts intestinal function, researchers are paving the way for the development of targeted therapies that could alleviate the discomfort of acute symptoms and potentially mitigate the risk of developing long COVID. As the scientific community continues to grapple with the long-term consequences of the pandemic, insights like these offer a beacon of hope for improved patient care and a deeper comprehension of viral pathogenesis. The ongoing investigation into viral persistence in the gut is particularly vital, promising to unlock further secrets of long COVID and inform strategies for complete recovery.
